Top

Published in:

01-02-2000

In Vitro Binding and Partitioning of Irinotecan (CPT-11) and its Metabolite, SN-38, in Human Blood

Authors: Olivier Combes, Jérôme Barré, Jean-Claude Duché, Laurent Vernillet, Yves Archimbaud, Michael P. Marietta, Jean-Paul Tillement, Saïk Urien

Published in: Investigational New Drugs | Issue 1/2000

Title: In Vitro Binding and Partitioning of Irinotecan (CPT-11) and its Metabolite, SN-38, in Human Blood
Authors: Olivier Combes
Jérôme Barré
Jean-Claude Duché
Laurent Vernillet
Yves Archimbaud
Michael P. Marietta
Jean-Paul Tillement
Saïk Urien
Publication date: 01-02-2000
Publisher: Kluwer Academic Publishers
Published in: Investigational New Drugs / Issue 1/2000
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1023/A:1006379730137

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 1/2000

Current Approaches and Future Strategies for Pancreatic Carcinoma

Development of Target-Based Antineoplastic Agents

Promising Approaches in Acute Leukemia

Instructions to Authors

Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

A Phase I Trial of Cisplatin Plus Decitabine, a New DNA-Hypomethylating Agent, in Patients with Advanced Solid Tumors and a Follow-Up Early Phase II Evaluation in Patients with Inoperable Non-Small Cell Lung Cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer